Biotech startup Bayland Cells has secured 140 million RMB in Series A funding to advance its affordable CAR-T cell therapies following the resolution of a legal dispute.
Impact
30/100
Current rank score
14.19
Source tier
Tier 2
Category
Funding
Firefly links to the original publisher. The summary above is AI-generated for orientation and may differ from the source. The “current rank score” decays over time so newer significant stories surface first.